Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-01-24
DOI
10.3389/fimmu.2022.781660
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of ROS in myeloid-derived suppressor cells through targeting fatty-acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy
- (2021) Adeleye Oluwatosin Adeshakin et al. CELLULAR IMMUNOLOGY
- Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma
- (2021) Obdulia Rabal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
- (2021) Nicola Tumino et al. Frontiers in Immunology
- The role of vitamin C in epigenetic cancer therapy
- (2021) Stine Ulrik Mikkelsen et al. FREE RADICAL BIOLOGY AND MEDICINE
- MDSC: Markers, development, states, and unaddressed complexity
- (2021) Samarth Hegde et al. IMMUNITY
- Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia
- (2021) Ramin Radpour et al. Frontiers in Oncology
- Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function
- (2021) Amy J. Petty et al. JCI Insight
- Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells
- (2021) Sho Hangai et al. NATURE IMMUNOLOGY
- Metabolic reprogramming and epigenetic modifications on the path to cancer
- (2021) Linchong Sun et al. Protein & Cell
- Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
- (2021) Lukman O. Afolabi et al. Frontiers in Immunology
- Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment
- (2021) Ellen N. Scott et al. Frontiers in Immunology
- The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer
- (2020) Andrea J. Luker et al. BMC IMMUNOLOGY
- Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
- (2020) Caroline Bergenfelz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches
- (2020) Zhihao Lu et al. NATURE
- Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma
- (2020) Handan Xiang et al. Cancer Immunology Research
- Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression
- (2020) Zhiqi Xie et al. OncoImmunology
- Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors
- (2020) Ayumi Hashimoto et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The future of cancer immunotherapy: microenvironment-targeting combinations
- (2020) Yonina R. Murciano-Goroff et al. CELL RESEARCH
- Pathogenesis of Herpes Stromal Keratitis: Immune Inflammatory Response Mediated by Inflammatory Regulators
- (2020) Li Wang et al. Frontiers in Immunology
- The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
- (2020) Alireza Labani-Motlagh et al. Frontiers in Immunology
- Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
- (2020) Pok Man Hau et al. Frontiers in Oncology
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
- (2020) Minjeong Yeon et al. Frontiers in Cell and Developmental Biology
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling
- (2020) Jimin Son et al. Cancer Immunology Research
- Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection
- (2020) Fan Tang et al. ANNALS OF SURGICAL ONCOLOGY
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
- (2020) Sreya Bagchi et al. Annual Review of Pathology-Mechanisms of Disease
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Immunity as a continuum of archetypes
- (2019) Adriana M. Mujal et al. SCIENCE
- Myeloid-Derived Suppressor Cells Confer Infectious Tolerance to Dampen Virus-Induced Tissue Immunoinflammation
- (2019) Roman Sarkar et al. JOURNAL OF IMMUNOLOGY
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer
- (2019) Karolina Okła et al. Frontiers in Immunology
- Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor
- (2019) Dehong Yan et al. Frontiers in Immunology
- Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
- (2019) Shixiang Wang et al. MOLECULES
- Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy
- (2019) Adeleye O. Adeshakin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis
- (2019) Dehong Yan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
- (2018) Richard P. Tobin et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells
- (2018) Zhiqi Xie et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Reciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer
- (2018) Xilan Yu et al. Frontiers in Genetics
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma
- (2017) Valeria Lucarini et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
- (2017) C C Wong et al. ONCOGENE
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
- (2017) Hee Seung Lee et al. Scientific Reports
- CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway
- (2017) Dawoon E. Jung et al. Scientific Reports
- Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro
- (2016) Hai-Fang Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Macrophages in Tissue Repair, Regeneration, and Fibrosis
- (2016) Thomas A. Wynn et al. IMMUNITY
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy
- (2016) Kei Ishibashi et al. OncoImmunology
- Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
- (2016) Michiel Kroesen et al. OncoImmunology
- The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
- (2016) Yusuke Tomita et al. OncoImmunology
- PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
- (2016) Tomoaki Iwata et al. Scientific Reports
- A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
- (2015) Deepa K. Krishnadas et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines
- (2015) JUNFEN MA et al. Molecular Medicine Reports
- Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
- (2015) Sung-Min Chun et al. PLoS One
- Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals
- (2015) Laura Gatti et al. Oncotarget
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
- (2014) Miranda L. Broz et al. CANCER CELL
- Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
- (2014) Manja Idorn et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Complexity and challenges in defining myeloid-derived suppressor cells
- (2014) Vera Damuzzo et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A
- (2014) J. Seo et al. ONCOLOGY REPORTS
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway
- (2013) Dehong Yan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Chronic but Not Acute Virus Infection Induces Sustained Expansion of Myeloid Suppressor Cell Numbers that Inhibit Viral-Specific T Cell Immunity
- (2013) Brian A. Norris et al. IMMUNITY
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
- (2013) Je-In Youn et al. NATURE IMMUNOLOGY
- Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma
- (2013) Bin Zhang et al. PLoS One
- Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
- (2013) Yana G. Najjar et al. Frontiers in Oncology
- CD14+S100A9+Monocytic Myeloid-derived Suppressor Cells and Their Clinical Relevance in Non–Small Cell Lung Cancer
- (2012) Po-Hao Feng et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma
- (2012) Eric J. Sherman et al. THYROID
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
- (2011) P. Goedegebuure et al. CURRENT CANCER DRUG TARGETS
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- (2011) Omar Khan et al. IMMUNOLOGY AND CELL BIOLOGY
- Myeloid derived suppressor cells in human diseases
- (2011) Tim F. Greten et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
- (2011) Jung Jin Hwang et al. INVESTIGATIONAL NEW DRUGS
- Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo
- (2011) Brian R. Rosborough et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non-Small Cell Lung Cancer
- (2011) M. Rodriguez-Paredes et al. Cancer Discovery
- Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-3
- (2009) Yaping Sun et al. JOURNAL OF IMMUNOLOGY
- Histone deacetylases and the immunological network: implications in cancer and inflammation
- (2009) A Villagra et al. ONCOGENE
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
- (2008) Xiang-Jiao Yang et al. MOLECULAR CELL
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started